NanoString Technologies is a Seattle Headquartered provider of life science tools for translational research and molecular diagnostics. Founded in 2003, the company’s technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications.

In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection, and in 2013 launched Prosigna™, its first in vitro diagnostic product for prognosis of early stage breast cancer, in Europe and Israel.

In July 2014 NanoString established their new UK Headquarters in Amersham, Buckinghamshire as part of continuing international expansion, working with UK Trade & Investment and local delivery partners Buckinghamshire Business First and Thames Valley Chamber of Commerce.

Whether it is the location, with its proximity to London and five airports within a 90 minutes drive, or the quality of life afforded to residents thanks to the natural surroundings and nationally-renowned schools, Buckinghamshire consistently sits at the top table for business.

“Operating from the healthcare cluster in Buckinghamshire provides us with the local talent and international connections we need to serve our clients and support this ambitious growth”  says Everton Robinson PhD, Director, EMEA-Life Sciences and Diagnostics, NanoString Technologies – Europe.

“2015 will be a year of continuing revenue growth, with the aim of expanding the organisation further across the UK and Europe in 2016.”

Thanks to its own desire for expansion and a fruitful partnership between stakeholders, NanoString is now a part of the vibrant Buckinghamshire business community.